Sandoz Inc. v. Amgen Inc.
Publisher |
Oyez
Media Type |
audio
Categories Via RSS |
Government & Organizations
National
Publication Date |
Apr 26, 2017
Episode Duration |
Unknown
A case in which the Court determined that the Biologics Price Competition and Innovation Act of 2009 allows for commercial notice of a “biosimilar product” to be effective if given prior to approval by the Food and Drug Administration (FDA), but that the Act’s notice requirement is not enforceable with an injunction.

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review